新型胃饥饿素受体反向激动剂PF-5190457与酒精联合给药:临床前安全实验与1b期人体实验室研究
结果示不良事件均为轻中度,药物不改变酒精浓度或主观效应,100mg每日两次可降低线索反应范式中的酒精渴求。
要点
- PF-5190457与酒精联用在大鼠和人体中均安全耐受,不良事件轻中度。
- 药物不改变酒精浓度、消除、酒精诱导的兴奋或镇静及给药期间情绪。
- 100mg每日两次可降低线索反应范式中的酒精渴求。
核心结论
- PF-5190457与酒精联用安全耐受,且100mg每日两次可降低酒精渴求,支持其作为酒精使用障碍潜在药物的继续研究。
研究设计与样本
- 临床前:大鼠测试PF-5190457与酒精对运动活性、翻正反射消失及血药浓度的影响。
主要发现
- 大鼠中PF-5190457不与酒精对运动活性或翻正反射消失的作用发生交互,酒精不影响血PF-5190457浓度。
- 人体中所有不良事件为轻中度,无需停药或减量。
- 药物剂量不改变酒精浓度或消除、酒精诱导的兴奋或镇静、或给药期间情绪。
- PF-5190457的潜在药效学标志物为酰基/总胃饥饿素比值和胰岛素样生长因子-1。
- PF-5190457(100mg每日两次)降低线索反应范式中的酒精渴求。
关键数值与推荐
- 人体研究剂量为安慰剂/0mg每日两次、50mg每日两次、100mg每日两次。
- 所有不良事件为轻中度,无需停药或减量。
临床怎么用
- PF-5190457与酒精联用未显示安全性信号,支持进一步开发用于酒精使用障碍。
- 100mg每日两次可能有助于降低酒精渴求,但需后续研究确认。
局限性
- 研究为实验室环境,未评估长期临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rodent studies indicate that ghrelin receptor blockade reduces alcohol consumption. However, no ghrelin receptor blockers have been administered to heavy alcohol drinking individuals. Therefore, we evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and behavioral effects of a novel ghrelin receptor inverse agonist, PF-5190457, when co-administered with alcohol. We tested the effects of PF-5190457 combined with alcohol on locomotor activity, loss-of-righting reflex (a measure of alcohol sedative actions), and on blood PF-5190457 concentrations in rats. Then, we performed a single-blind, placebo-controlled, within-subject human study with PF-5190457 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.). Twelve heavy drinkers during three identical visits completed an alcohol administration session, subjective assessments, and an alcohol cue-reactivity procedure, and gave blood samples for PK/PD testing. In rats, PF-5190457 did not interact with the effects of alcohol on locomotor activity or loss-of-righting reflex. Alcohol did not affect blood PF-5190457 concentrations. In humans, all adverse events were mild or moderate and did not require discontinuation or dose reductions. Drug dose did not alter alcohol concentration or elimination, alcohol-induced stimulation or sedation, or mood during alcohol administration. Potential PD markers of PF-5190457 were acyl-to-total ghrelin ratio and insulin-like growth factor-1. PF-5190457 (100 mg b.i.d.) reduced alcohol craving during the cue-reactivity procedure. This study provides the first translational evidence of safety and tolerability of the ghrelin receptor inverse agonist PF-5190457 when co-administered with alcohol. PK/PD/behavioral findings support continued research of PF-5190457 as a potential pharmacological agent to treat alcohol use disorder.
引用
- Lee MR, Tapocik JD, Ghareeb M, et al. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. Mol Psychiatry. 2018. PMID: 29728704. doi:10.1038/s41380-018-0064-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。